Article Sidebar

PDF
Date Published: 29/11/2024
Abstract Views: 103
Views PDF: 64
DOI: https://doi.org/10.51298/vmj.v544i2.11913
Issue
Vol. 544 No. 2 (2024): Vietnam Medical Journal
Section
Các bài báo
How to Cite
Tuan Anh, P. ., & Phuong Anh, N. . (2024). SINGLE-AGENT TOPOTECAN IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: A STUDY IN VIET NAM NATIONAL CANCER HOSPITAL. Vietnam Medical Journal, 544(2). https://doi.org/10.51298/vmj.v544i2.11913

SINGLE-AGENT TOPOTECAN IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: A STUDY IN VIET NAM NATIONAL CANCER HOSPITAL

Pham Tuan Anh1,, Nguyen Phuong Anh1
1 Optimal Clinical Care Department, National Cancer Hospital of Viet Nam

Main Article Content

Abstract

Platinum-based doublet chemotherapy is still supposed as standard regimen in ovarian cancer. However, the rate of relapse or refractory is also very high and vary from 80-85% with stage III-IV ovarian cancer [1]. The prognosis of platinum-resistant ovarian cancer (relapse or refractory within 6 months after initial treatment) has a median survival of 9–12 months and less than 15% respond to subsequent chemotherapy [2]. Thesedays, there are several agents were introduced to control this disease such as Docetaxel, Etoposid, Gemcitabine, Liposomal doxorubicin with overall response rate vary from 12-27% [3] [4] [5]. The objective of this study was to evaluate response and toxicity of 5-day Topotecan chemotherapy in women with primary and secondary platinum-resistant epithelial ovarian cancer.

Article Details

Keywords

Topotecan, Ovarian Cancer, Platinum-Resistant

References

1. Thuan Tran Van et al. 2014, Diagnosis and Treatment of Cancer Diseases, Hanoi Medical Publishing House. 339-351.
2. Davis et al. 2014, “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecologic Oncology 133.624–631.
3. Gordon AN, Granai CO, Róe PG et al. (2000). Phase II study of liposimal doxorubicin in platinum and paclitaxel refractory epithelial ovarian cancer. J Clin Oncol. 18, 3093-3097.
4. Rose PG, Blessing JA, Mayer SR et al. (1998). Prolonged oral etoposide as second line therapy for platinum resistent and platinum senstive ovarian cancer. A Gyecologic Oncology Group study. J Clin Oncol. 16, 405- 410.
5. Gordon AN, Fleage JT, Guthrie D, et al (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19
6. Bray F., Ferlay J., Soerjomataram I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394–424.
7. Peng LH, ChenXY, Wu TX, Topotecan for ovarian cancer. Cochrance Database Syst Rev 2008; CD00589
8. Jalid Sehouli, Dirk Stengel, Philipp Harter, et al (2010): Topotecan weekly versus Conventional 5- day schedule in patients with Platinum – resistant ovarian cancer: A randomized multicenter pha II trial of the north- Eastern German society of gynecological oncology ovarian cancer stady group. J Clin Oncol 29:242-248.
9. Bokkel Huinink W (1997), Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183-93.
10. Gordon AN, Fleage JT, Guthrie D, et al (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19.